Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing

In this article:

  • JUVÉDERM® VOLUMA® XC is the One and Only Hyaluronic Acid Dermal Filler Indicated to Treat Cheeks, Chin, and Now Moderate to Severe Temple Hollowing1,2

  • Only Allergan Aesthetics, the Makers of BOTOX® Cosmetic (onabotulinumtoxinA), has FDA-Approved Injectables to Treat More Than 90% of the Face2-8

IRVINE, Calif., Oct. 2, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVÉDERM® VOLUMA® XC for temple hollowing. Following its U.S. FDA approval in March 2024, JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) filler approved to treat moderate to severe temple hollowing in adults over 21.1,2 The JUVÉDERM® Collection of Fillers is the number one chosen HA dermal filler brand by patients and providers, and now offers the largest range of treatment indications to meet patients' aesthetic goals.2-7

JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing is Now Available Nationwide. Actual patient treated with 2.9 mL of JUVÉDERM® VOLUMA® XC in the temples, 2.1 mL of JUVÉDERM® VOLUMA® XC in the midface, 2.5 mL of JUVÉDERM® VOLUMA® XC in the chin, 0.7 mL of JUVÉDERM® VOLBELLA® XC in the infraorbital hollows, and 1.0 mL of JUVÉDERM® VOLLURE® XC in the moderate to severe facial wrinkles and folds.
JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing is Now Available Nationwide. Actual patient treated with 2.9 mL of JUVÉDERM® VOLUMA® XC in the temples, 2.1 mL of JUVÉDERM® VOLUMA® XC in the midface, 2.5 mL of JUVÉDERM® VOLUMA® XC in the chin, 0.7 mL of JUVÉDERM® VOLBELLA® XC in the infraorbital hollows, and 1.0 mL of JUVÉDERM® VOLLURE® XC in the moderate to severe facial wrinkles and folds.

"In the months since approval, our focus has been on developing and implementing a robust training protocol designed to ensure providers are well versed in the science needed to inject the temple area," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie. "We will continue to provide comprehensive training for this treatment area, as we do with all Allergan Aesthetics products. We look forward to seeing the beautiful results our customers will achieve by adding JUVÉDERM® VOLUMA® XC for temple into their pan-facial approach."

As the most awarded filler collection in the U.S.,9* the JUVÉDERM® Collection of Fillers boasts impressive patient satisfaction. As a key product in the collection, JUVÉDERM® VOLUMA® XC when used in the temples, delivers:

  • A natural look and feel: Approximately 90% of patients were satisfied with the natural look and feel of their temples at three months after temple treatment.2†

  • Long-lasting improvement: More than 85% of patients reported an overall aesthetic improvement one-month post-treatment, with results lasting up to 13 months.11‡§

  • High satisfaction: 98% of patients treated in the temple would recommend temple treatment to a friend.2

  • Established safety: JUVÉDERM® VOLUMA® XC for temples has an acceptable safety profile and is approved for adults of all Fitzpatrick skin types over 21 years of age.10

"The number one facial concern patients have is the eye area,12 so it is essential to consider treating the temples as part of a comprehensive treatment plan. With the approval and training-led launch of JUVÉDERM® VOLUMA® XC, licensed aesthetic providers like me receive advanced training to treat this area," said Board-certified plastic surgeon Christopher C. Surek, DO, FACS. "Treatment with JUVÉDERM® VOLUMA® XC in the temples creates a balanced and youthful appearance.1 The efficacy of JUVÉDERM® VOLUMA® XC is evident in the immediate lift it creates,1 making it an ideal choice for patients seeking subtle, natural-looking results."